A look into Gossamer Bio Inc. (GOSS)’s deeper side

Gossamer Bio Inc. (NASDAQ: GOSS) stock jumped 5.53% on Monday to $2.10 against a previous-day closing price of $1.99. With 4.52 million shares changed hands, the volume of the stock remained lighter than its average volume of 5.39 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.1600 whereas the lowest price it dropped to was $1.9900. The 52-week range on GOSS shows that it touched its highest point at $15.19 and its lowest point at $1.57 during that stretch. It currently has a 1-year price target of $7.42. Beta for the stock currently stands at 1.10.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GOSS was down-trending over the past week, with a drop of -10.26%, but this was up by 0.96% over a month. Three-month performance dropped to -83.68% while six-month performance fell -82.26%. The stock lost -80.32% in the past year, while it has lost -3.23% so far this year. A look at the trailing 12-month EPS for GOSS yields -2.89 with Next year EPS estimates of -2.38. For the next quarter, that number is -0.62. This implies an EPS growth rate of 12.00% for this year and 13.50% for next year.

Float and Shares Shorts:

At present, 91.18 million GOSS shares are outstanding with a float of 89.93 million shares on hand for trading. On Oct 13, 2022, short shares totaled 17.66 million, which was 18.80% higher than short shares on Sep 14, 2022. In addition to Mr. Faheem Hasnain as the firm’s Co-Founder, CEO, Pres & Chairman, Mr. Bryan Giraudo serves as its COO & CFO.

Institutional Ownership:

Through their ownership of 76.55% of GOSS’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 55.93% of GOSS, in contrast to 53.68% held by mutual funds. Shares owned by individuals account for 16.83%. As the largest shareholder in GOSS with 29.47% of the stake, SSgA Funds Management, Inc. holds 27,843,985 shares worth 27,843,985. A second-largest stockholder of GOSS, HHLR Advisors Ltd., holds 7,420,974 shares, controlling over 7.86% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in GOSS, holding 7,187,655 shares or 7.61% stake. With a 28.79% stake in GOSS, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 27,198,348 shares are owned by the mutual fund manager. The Direxion Daily S&P Biotech Bull 3, which owns about 2.90% of GOSS stock, is the second-largest Mutual Fund holder. It holds 2,740,924 shares valued at 5.95 million. Vanguard Total Stock Market Index holds 2.56% of the stake in GOSS, owning 2,417,239 shares worth 5.25 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GOSS since 13 analysts follow the stock currently. There are 9 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With GOSS analysts setting a high price target of $15.00 and a low target of $2.00, the average target price over the next 12 months is $7.42. Based on these targets, GOSS could surge 614.29% to reach the target high and fall by -4.76% to reach the target low. Reaching the average price target will result in a growth of 253.33% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. GOSS will report FY 2022 earnings on 03/01/2024. Analysts have provided yearly estimates in a range of -$2.68 being high and -$2.84 being low. For GOSS, this leads to a yearly average estimate of -$2.75. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Gossamer Bio Inc. surprised analysts by -$0.01 when it reported -$0.65 EPS against a consensus estimate of -$0.64. The surprise factor in the prior quarter was -$0.05. Based on analyst estimates, the high estimate for the next quarter is -$0.57 and the low estimate is -$0.67. The average estimate for the next quarter is thus -$0.62.

Summary of Insider Activity:

Insiders traded GOSS stock several times over the past three months with 0 Buys and 4 Sells. In these transactions, 0 shares were bought while 19,266 shares were sold. The number of buy transactions has increased to 4 while that of sell transactions has risen to 13 over the past year. The total number of shares bought during that period was 166,433 while 89,152 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *